LL-37 (cathelicidin)
Recovery · Antimicrobial peptide
Tier D+
What this is
Used by some protocols targeting biofilm-associated chronic infections (CIRS/Lyme communities). Essentially no clinical trial safety data in humans for exogenous administration. Speculative application.
Mechanism
Endogenous cationic host-defense peptide from cathelicidin; broad antimicrobial activity; immunomodulatory and wound healing effects; VDR-regulated
Dose & route
No established human dosing protocol
Citations
- https://pubmed.ncbi.nlm.nih.gov/31618880/
- https://pubmed.ncbi.nlm.nih.gov/27006251/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6694145/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.